GLP-1 receptor agonists stories

Aug 5, 2026

Mounjaro Found to Reduce Heart Attack Risk by 33% in Type 2 Diabetes Patients with Heart Disease

A new study shows that tirzepatide (Mounjaro), a GLP-1 receptor agonist drug, reduces heart attack risk by 33% when added to standard care for patients with both type 2 diabetes and existing heart disease. The findings come as worldwide sales of the drug doubled to £13.8 billion in the first half of 2026.

Aug 5, 2026·5 sources

Jul 23, 2026

Eli Lilly's retatrutide shows positive Phase 3 results, plans Q1 2027 FDA application

Eli Lilly announced positive results from two additional Phase 3 trials of its experimental obesity drug retatrutide (a 'triple-G' GLP-1 receptor agonist), showing it did not increase overall heart risk. The company plans to submit an FDA application in Q1 2027.

Jul 23, 2026·3 sources

Top claims

▪At one year of treatment, the risk of major adverse cardiovascular events (MACE) was 2.9% in the tirzepatide group compared to 4.4% in the sitagliptin group, representing a 32% relative reduction.
▪Adding the GLP-1 receptor agonist drug tirzepatide (marketed as Mounjaro) to standard care for patients with type 2 diabetes and heart disease is associated with a lower risk of major cardiovascular events.
▪Tirzepatide was associated with lower rates of infections requiring hospital admission, preventing one admission for every 48 patients, and prevented one death from any cause for every 122 patients.

Subtopics

GLP-1 medications Cardiovascular health.Retatrutide Eli Lilly

Clinical trials

Related timelines

GLP-1 receptor agonists stories

Mounjaro Found to Reduce Heart Attack Risk by 33% in Type 2 Diabetes Patients with Heart Disease

Eli Lilly's retatrutide shows positive Phase 3 results, plans Q1 2027 FDA application

Related timelines

US Congress

Iran War

Strait of Hormuz blockage

Trump administration

AI Data Center Gold Rush